-
A ranar 11 ga Yuni, Kelun-Biotech ta sanar da cewa Cibiyar Nazarin Magunguna (CDE) ta National Med... ta ba da izinin samar da maganin TROP2 ADC sac-TMT (佳泰莱) wanda aka samar da kansa, tare da haɗin gwiwar PD-L1 monoclonal antibody tagitanlimab (科泰莱).Kara karantawa»
-
A ranar 29 ga Mayu, Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta amince da tallan Zanidatamab, wanda BeiGene ya gabatar, don maganin marasa lafiya da ke fama da cutar kansar biliary tract (BTC) wadda ba a iya cirewa ba a gida ko kuma wadda ta kamu da cutar kansar biliary tract (BTC) waɗanda a baya suka sami maganin tsarin jiki kuma suna da yawan HER2...Kara karantawa»
-
A ranar 4 ga Yuni, 2025, Akeso ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta amince da maganin rigakafi na PD-1/CTLA-4 na farko a cikin aji biyu, cadonilimab, don maganin farko na ciwon daji na mahaifa mai dorewa, mai sake dawowa, ko kuma wanda ya kamu da cutar kansar mahaifa, tare da haɗin gwiwa da platinum...Kara karantawa»
-
A ranar 29 ga Mayu, Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta amince da maganin HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) don tallatawa. An nuna shi azaman maganin da aka yi amfani da shi don magance manyan marasa lafiya da ba a iya cirewa ba a cikin gida ko kuma waɗanda ba su da ƙanana ...Kara karantawa»
-
A ranar 21 ga Mayu, 2025, InnoCare Pharma ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa ta China (NMPA) ta amince da Minjuvi® (tafasitamab), wani maganin hana daukar ciki na Fc-modified cytolytic CD19 wanda ke nufin maganin rigakafi na monoclonal, tare da lenalidomide, sannan kuma maganin Minjuvi monotherapy, don magance...Kara karantawa»
-
A ranar 22 ga Mayu, 2025, Allist Pharmaceuticals ta sanar da cewa sabuwar maganinta mai suna Airuikai (Glecirasib Citrate Tablets), wani maganin hana KRAS-G12C, an amince da shi a hukumance don ƙaddamar da kasuwa ta Hukumar Kayayyakin Lafiya ta Ƙasa (NMPA). Amincewar ta ba da damar amfani da Airuikai don maganin...Kara karantawa»
-
A ranar 22 ga Mayu, 2025, Kelun Bio ta sanar da cewa an karɓi aikace-aikacen sabon nuni na antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, wanda kuma aka sani da SKB264/MK – 2870) (®) daga Cibiyar Kimanta Magunguna (...Kara karantawa»
-
A cikin Yaƙi Mai Dorewa Da Kamuwa Da Cutar Kansa, Sabbin Makamai Masu Yaƙi Da Cutar Kansa Suna Fitowa Ci Gaba, Suna Kawo Sabuwar Fata Ga Marasa Lafiya A cikin dogon yaƙin da ke tsakanin mutane da cutar kansa, sabbin makamai masu yaƙi da cutar kansa suna fitowa ɗaya bayan ɗaya, suna kawo sabuwar fata ga marasa lafiya. A matsayin sabon salo mai haske...Kara karantawa»
-
A shekarar 2021, wata tsohuwa mai shekaru 67 da ta kamu da cutar kansar pancreas ta ƙirƙiri wani abin al'ajabi na likitanci. Bayan ta fuskanci tiyata, zagaye da dama na chemotherapy, da kuma gazawar maganin TIL, gwajin asibiti na maganin ƙwayoyin TCR-T da ta shiga ya sa ƙwayoyin huhu suka ragu da kashi 72% cikin watanni 6...Kara karantawa»
-
A ranar 12 ga Mayu, 2025, CARsgen ta sanar da bayanai na farko na asibiti don CT0596, wani nau'in CAR-T mai niyya ga BCMA wanda aka haɓaka ta amfani da dandamalin THANK-u Plus™. A halin yanzu ana tantance CT0596 a cikin wani bincike na asibiti na farko don sake dawowa/ragewa da yawa na myeloma (R/R MM) ko sake dawowa/ragewa...Kara karantawa»
-
A ranar 9 ga Mayu, 2025, Hansoh Pharmaceutical ta sanar da cewa an amince da wani sabon alama ga Ameile (almonertinib mesylate allunan) don tallatawa. Sabuwar alamar tana nufin maganin taimako ga manya marasa lafiya da ke fama da cutar kansar huhu ta ƙwayoyin halitta (NSCLC) waɗanda ciwonsu ke da tasirin ci gaban epidermal...Kara karantawa»
-
A ranar 1 ga Mayu, 2025, Hansoh Pharmaceutical ta sanar da cewa maganin rigakafi na B7-H4 da aka haɓaka da kansa (ADC) HS-20089 na ƙungiyar don allura ya sami izinin shiga cikin maganin warkewa wanda Hukumar Kayayyakin Lafiya ta Ƙasa (NMPA) ta China ta ayyana, wanda...Kara karantawa»
Cibiyar likitanci ta haɗin gwiwa ta Asibitin Ciwon Daji na Beijing